A Phase II Study Evaluating the Use of Concurrent Cetuximab, Irinotecan, Oxaliplatin and UFT in the First Line Treatment of Patients With Metastatic Colorectal Cancer.

Trial Profile

A Phase II Study Evaluating the Use of Concurrent Cetuximab, Irinotecan, Oxaliplatin and UFT in the First Line Treatment of Patients With Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Tegafur/uracil (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms eSCOUT
  • Most Recent Events

    • 10 Jun 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 26 Apr 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 26 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top